Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
According to Mesa Laboratories, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.15. At the end of 2023 the company had a P/B ratio of 2.36.
Year | P/B ratio |
---|---|
2024 | 4.15 |
2023 | 2.36 |
2022 | 3.37 |
2021 | 2.98 |
2020 | 4.32 |
2019 | 7.89 |
2018 | 5.60 |
2017 | 4.61 |
2016 | 4.10 |
2015 | 3.46 |
2014 | 4.83 |
2013 | 3.30 |
2012 | 3.69 |
2011 | 2.56 |
2010 | 2.66 |
2009 | 1.84 |
2008 | 2.93 |
2007 | 2.89 |
2006 | 2.83 |
2005 | 2.74 |
2004 | 1.90 |
2003 | 1.37 |
2002 | 1.86 |
2001 | 1.43 |
2000 | 1.31 |
1999 | 1.74 |
1998 | 2.23 |
1997 | 2.33 |
1996 | 3.86 |
1995 | 1.73 |
1994 | 2.42 |
1993 | 2.56 |
1992 | 4.14 |
1991 | 3.89 |
1990 | 1.47 |
1989 | 0.78 |
1988 | 0.79 |